News Digging > Popular > PSA-based endpoints should not be used as surrogate endpoints for overall survival in men with recurrent prostate cancer
PSA-based endpoints should not be used as surrogate endpoints for overall survival in men with recurrent prostate cancer
PSA-based endpoints should not be used as surrogate endpoints for overall survival in men with recurrent prostate cancer,Results from a surrogacy analysis of the NRG-RTOG 9601 trial indicated that biochemical failure was not an adequate surrogate endpoint for overall

PSA-based endpoints should not be used as surrogate endpoints for overall survival in men with recurrent prostate cancer

Results from a surrogacy analysis of the NRG-RTOG 9601 trial indicated that biochemical failure was not an adequate surrogate endpoint for overall